Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.
IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients
Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other?
Sex differences in autoimmune disease.
TECFIDERA prescribing information
FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination.
Experimental models of spontaneous autoimmune disease in the central nervous system.
Demyelination of the hippocampus is prominent in the cuprizone model.
Origin, fate and dynamics of macrophages at central nervous system interfaces.
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
The neuroendocrine axis in patients with multiple sclerosis.
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Effects of dimethyl fumarate on neuroprotection and immunomodulation.
Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response.
Optical coherence tomography reflects brain atrophy in MS: A four year study.
Sex differences in autoimmune diseases.
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
Pregnancy and multiple sclerosis.
A New Colour Reaction on Copper and Certain Carbonyl Compounds

Pages